- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioma, Refractory Glioma, WHO Grade III Glioma
- Interventions
- HER2(EQ)BBζ/CD19t+ T cells, Laboratory Biomarker Analysis, Leukapheresis
- Biological · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 3,059
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor, Metastatic Bladder Cancer
- Interventions
- RX-3117
- Drug
- Lead sponsor
- Processa Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 9 more
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, fludarabine phosphate
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 215
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 140 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Irvine, California • Orange, California + 9 more
- Conditions
- Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
- Interventions
- rosiglitazone, XL184
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Soft Tissue Metastases, Stage IV Prostate Cancer
- Interventions
- sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
- Biological · Radiation · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 3
- States / cities
- Duarte, California • Pasadena, California • Salt Lake City, Utah
- Conditions
- Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
- Interventions
- educational intervention, questionnaire administration, quality-of-life assessment
- Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 32 more
- Conditions
- Lymphoma
- Interventions
- Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Milvexian, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 162
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 19
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 15 more
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Radiation Toxicity
- Interventions
- management of therapy complications, quality-of-life assessment
- Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 0 Years to 120 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 223
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 174 more
- Conditions
- Systemic Scleroderma
- Interventions
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Plerixafor, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 12
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 5 more
- Conditions
- Hematologic Malignancies
- Interventions
- Educational Intervention, Health Telemonitoring, Questionnaire Administration, Best Practice
- Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
- Interventions
- ziv-aflibercept
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 5 more
- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 11 more
- Conditions
- Inflammatory Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer, Stage IIB Breast Cancer, Estrogen Receptor Negative, Progesterone Receptor Negative, HER2/Neu Negative
- Interventions
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • South Pasadena, California
- Conditions
- Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type, Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Filgrastim, Fludeoxyglucose F-18, Multigated Acquisition Scan, Pegfilgrastim, Prednisone, Questionnaire Administration, Ruxolitinib Phosphate, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced Solid Tumors With HER2 Abnormalities, Advanced Solid Tumors With HER3 Abnormalities
- Interventions
- TAS0728
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Neoplasms, Lymphoma
- Interventions
- ABT-888, Cyclophosphamide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Duarte, California • Bethesda, Maryland
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 429
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more
- Conditions
- Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
- Interventions
- AG-120, Placebo
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 19 more
- Conditions
- Obesity, Overweight
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 15,374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 165
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 141 more
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 5,511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2037
- U.S. locations
- 111
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 98 more